Skye Bioscience, INC. (SKYE) — 10-Q Filings

All 10-Q filings from Skye Bioscience, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Skye Bioscience's Losses Mount Amid R&D Surge, Nimacimab Fails Phase 2a — Nov 10, 2025 Risk: high
Skye Bioscience, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $41,482,851, a substantial rise from $1
Skye Bioscience Losses Widen Amid R&D Push — Aug 7, 2025 Risk: high
Skye Bioscience, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-revenue stage as a pharmaceutical company. T
Skye Bioscience Q1 2025 10-Q Filed — May 8, 2025 Risk: medium
Skye Bioscience, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported financial results for the first quarter of 2025, detailing its a
Skye Bioscience Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
Skye Bioscience, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and operational updates. Key financial fig
Skye Bioscience Files Q2 2024 10-Q — Aug 9, 2024 Risk: medium
Skye Bioscience, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business operat
Skye Bioscience, Inc. Files 10-Q for Period Ending March 31, 2024 — May 10, 2024 Risk: low
Skye Bioscience, Inc. (SKYE) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Skye Bioscience, Inc. filed its 10-Q report for the quarterly period

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX